CLN — Celon Pharma SA Income Statement
0.000.00%
Last trade - 00:00- PLN823.03m
- PLN734.08m
- PLN216.57m
- 70
- 23
- 50
- 43
Annual income statement for Celon Pharma SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | PAS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 102 | 160 | 199 | 195 | 217 |
| Cost of Revenue | |||||
| Gross Profit | 78.9 | 123 | 137 | 128 | 150 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 95.3 | 164 | 210 | 232 | 244 |
| Operating Profit | 6.9 | -3.67 | -10.5 | -37.3 | -27.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 7.81 | -5.59 | -15.1 | -36.4 | -20 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 11.9 | -0.917 | -11.6 | -39.3 | -28.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 11.9 | -0.917 | -11.6 | -39.3 | -28.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 11.9 | -0.917 | -11.6 | -39.3 | -28.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.255 | -0.027 | -0.251 | -0.772 | -0.565 |
| Dividends per Share |